These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 10509572)

  • 1. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group.
    Pellegrin I; Izopet J; Reynes J; Denayrolles M; Montes B; Pellegrin JL; Massip P; Puel J; Fleury H; Segondy M
    AIDS; 1999 Sep; 13(13):1705-9. PubMed ID: 10509572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy.
    Mouroux M; Descamps D; Izopet J; Yvon A; Delaugerre C; Matheron S; Coutellier A; Valantin MA; Bonmarchand M; Agut H; Massip P; Costagliola D; Katlama C; Brun-Vezinet F; Calvez V
    Antivir Ther; 2001 Sep; 6(3):179-83. PubMed ID: 11808752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.
    Coakley EP; Gillis JM; Hammer SM
    AIDS; 2000 Jan; 14(2):F9-15. PubMed ID: 10708277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
    Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Didanosine dosed once daily is equivalent to twice daily dosing for patients on double or triple combination antiretroviral therapy. The AI454-147 Team.
    Kazatchkine MD; Van PN; Costagliola D; Mohammed AS; Ledeine JM; Troccaz M; Belec L
    J Acquir Immune Defic Syndr; 2000 Aug; 24(5):418-24. PubMed ID: 11035612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy.
    Pellegrin I; Segondy M; Garrigue I; Izopet J; Montes B; Pellegrin JL; Reynes J; Massip P; Puel J; Fleury H
    J Acquir Immune Defic Syndr; 2000 Dec; 25(5):465-6. PubMed ID: 11141248
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter.
    de Mendoza C; Ramos JT; Ciria L; Fortuny C; García FJ; de José MI; Asensi F; Soriano V
    HIV Clin Trials; 2002; 3(1):9-16. PubMed ID: 11819180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients.
    Raffi F; Reliquet V; Auger S; Besnier JM; Chennebault JM; Billaud E; Michelet C; Perre P; Lafeuillade A; May T; Billaudel S
    AIDS; 1998 Oct; 12(15):1999-2005. PubMed ID: 9814868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
    Ait-Khaled M; Rakik A; Griffin P; Cutrell A; Fischl MA; Clumeck N; Greenberg SB; Rubio R; Peters BS; Pulido F; Gould J; Pearce G; Spreen W; Tisdale M; Lafon S;
    Antivir Ther; 2002 Mar; 7(1):43-51. PubMed ID: 12008787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
    Principi N; Marchisio P; Esposito S; Rossi P; Gattinara GC; Galli L; Gabiano C; Zuccotti GV; Orlandi P
    AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1653-9. PubMed ID: 9870319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.
    Lafeuillade A; Poggi C; Hittinger G; Chadapaud S
    HIV Med; 2001 Oct; 2(4):231-5. PubMed ID: 11737402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S; La Seta Catamancio S; Sheridan F; Parker D
    J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
    Monno L; Cargnel A; Soranzo ML; Chirianni A; Ferraro T; Di Stefano M; Angarano G
    Antivir Ther; 1999; 4(4):195-202. PubMed ID: 10723498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
    Røge BT; Katzenstein TL; Obel N; Nielsen H; Kirk O; Pedersen C; Mathiesen L; Lundgren J; Gerstoft J
    Antivir Ther; 2003 Apr; 8(2):173-82. PubMed ID: 12741630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
    Demeter LM; Meehan PM; Morse G; Gerondelis P; Dexter A; Berrios L; Cox S; Freimuth W; Reichman RC
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):136-44. PubMed ID: 9052722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
    Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
    AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.